Breaking Finance News

Cambridge Cognition Holdings (LON:COG) target maintained at 115.00GBX, issued a ratings update earlier today by finnCap

Indicating a possible upside of 0.39%, finnCap hold steady the target price of Cambridge Cognition Holdings (LON:COG) at 115.00GBX

On 09/22/2016, finnCap released a statement on Cambridge Cognition Holdings (LON:COG) upped the target price from 0.00GBX to 115.00GBX that suggested an upside of 0.54%.

Having a price of 82.50GBX, Cambridge Cognition Holdings (LON:COG) traded -1.78% lower on the day. With the last close up 81.04% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Cambridge Cognition Holdings has recorded a 50-day average of 63.23GBX and a two hundred day average of 45.85GBX. Volume of trade was down over the average, with 36,491 shares of COG changing hands under the typical 41,777

Performance Chart

Cambridge Cognition Holdings (LON:COG)

With a total market value of 0 GBX, Cambridge Cognition Holdings has with a 52 week low of 30.00GBX and a 52 week high of 105.00GBX .

Also covering Cambridge Cognition Holdings's target, a total of 1 firm has reported on Cambridge Cognition Holdings. The 12-month price target is 100.00GBX with zero brokerages rating the company a strong buy, 0 brokers rating the stock a buy, zero equity analysts rating the company a hold, zero brokerages rating the company a underperform, and lastly zero brokerages rating the stock a sell.

Brief Synopsis On Cambridge Cognition Holdings (LON:COG)

Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. It also offers Cantab Insight for dementia assessment in secondary care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.